OVID
Ovid Therapeutics Inc

6,108
Mkt Cap
$115.36M
Volume
622,043.00
52W High
$2.01
52W Low
$0.2425
PE Ratio
-3.17
OVID Fundamentals
Price
$1.61
Prev Close
$1.62
Open
$1.60
50D MA
$1.52
Beta
1.11
Avg. Volume
1.62M
EPS (Annual)
-$0.3728
P/B
2.58
Rev/Employee
$24,608.70
Loading...
Loading...
News
all
press releases
Ovid Therapeutics Names Petra Kaufmann Chief Medical Officer
(RTTNews) - Ovid Therapeutics Inc. (OVID) on Tuesday announced the appointment of Petra Kaufmann as its chief medical officer...
Nasdaq News: Markets·9d ago
News Placeholder
More News
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has...
MarketBeat·20d ago
News Placeholder
FY2025 EPS Forecast for Ovid Therapeutics Lowered by Analyst
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Wedbush dropped their FY2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research report issued to...
MarketBeat·24d ago
News Placeholder
FY2025 EPS Forecast for Ovid Therapeutics Cut by Analyst
Ovid Therapeutics (NASDAQ:OVID - Free Report) - B. Riley lowered their FY2025 earnings per share (EPS) estimates for Ovid Therapeutics in a research report issued on Wednesday, November 12th. B...
MarketBeat·24d ago
News Placeholder
William Blair Issues Pessimistic Forecast for OVID Earnings
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at William Blair cut their FY2025 EPS estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, November...
MarketBeat·24d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·25d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Posts Earnings Results, Misses Estimates By $0.02 EPS
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·28d ago
News Placeholder
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -13.33% and -61.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of +200.00% and +1.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +149.06% and +145.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago

Latest OVID News

View

Advertisement|Remove ads.

Advertisement|Remove ads.